摘要:
Novel therapeutic agents useful as inhibitors of HLE are provided. The compounds have structural formula (I) wherein R through R , m, n and p are as defined herein. Methods of using the compounds of formula (I) to inhibit serine proteases and to treat physiological conditions and disease states associated with elevated HLE levels are also provided, as are pharmaceutical compositions containing the compounds.
摘要:
The invention provides chemistry libraries containing fused 3,1-benzoxazine-4-ones. The invention also provides methods for the construction of fused 3,1-benzoxazine-4-one containing libraries. The invention further provides methods for the identification of bioactive, 3,1-benzoxazine-4-ones from those libraries.
摘要:
4H-3,1-Benzoxazin-4-one compounds represented by general formula (I) (wherein R represents a hydrogen atom or an alkyl group, A represents an amino acid residue or a peptide containing 2 to 3 amino acid residues (provided that side chains of these amino acid residues may be protected by protective groups), X represents an alkyl group, a fluoroalkyl group, OR1 or NHR1 (wherein R1 represents an alkyl group) and Y represents an amino group-protective group) and their salts are disclosed. They show an excellent inhibitory action on serine protease, particularly human leukocyte elastase, thus being useful as the component of elastase-inhibiting drugs.
摘要:
The present invention relates to methods for preparing compounds of formula (I): or suitable salts thereof useful as inhibitors of voltage-gated sodium channels and calcium channels. The invention also relates to methods for preparing intermediates related thereto.
摘要:
Die Erfindung beschreibt Oxazin/thi)onverbindungen der Formel (I), in der die Variablen Z, R 1 , R 2 , R 3 und n die in Anspruch (1) angegebenen Bedeutungen aufweisen und A ein über zwei C-Atome mit dem Oxazin(thi)onring anellierter 5- oder 6-gliedriger Carbocyclus oder ein 5- oder 6-gliedriger Heterocyclus mit 1, 2 oder 3 Heteroatomen, ausgewählt unter N, O und S, ist, sowie die landwirtschaftlich brauchbaren Salze der Oxazin(thi)onverbindungen (I). Ausserdem beschreibt die Erfindung die Verwendung von Verbindungen (I) und ihrer Salze zur Bekämpfung pflanzenpathogener Pfilze, Mittel, welche die Verbindungen (I) und/oder ihre Salze in einer fungizid wirksamen Menge enthalten sowie ein Verfahren zur Bekämpfung von pflanzenpathogenen Pilzen, bei dem man die Pilze oder die von Pilsbefall bedrohten Materialien, Pflanzen, Saatgüter oder den Erdboden mit einer fungizid wirksamen Menge mindestens einer Verbindung der Formel (I) gemäss Anspruch (1) und/oder eines Salzes von (I) behandelt.
摘要:
The present invention relates to novel compounds, pharmaceutical compositions containing the same as well as a method for treatment of parasitic disorders, wherein said compounds are administered. The present compounds are especially well suited for treatment of coccidiosis, particularly in poultry, and they have general formula (I), where Y is S or O and R is as defined in the specification.
摘要:
The use of a compound, comprising formula (I) or a salt, ester, amide of prodrug thereof in the inhibition of an enzyme whose preferred mode of action is to catalyse the hydrolysis of an ester functionality e.g. in the control and inhibition of unwanted enzymes in products and processes. The compounds are also useful in medicine e.g. in the treatment of obesity and related conditions. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I) A is an optionally substituted 6-membered aromatic or heteroaromatic ring; and R is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups.
摘要:
A class of compounds for the treatment of viral infections. Compounds of particular interest are defined by formula (I) wherein R - R are as defined herein, or a pharmaceutically-acceptable salt thereof.